We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Momenta Pharmaceuticals Inc | NASDAQ:MNTA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.48 | 47.70 | 52.45 | 0 | 01:00:00 |
By Colin Kellaher
Johnson & Johnson on Wednesday said it agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion, or $52.50 a share, in cash.
The deal represents a roughly 70% premium to Tuesday's closing price of $30.81 for Momenta, a Cambridge, Mass., biotechnology company focused on developing treatments of rare immune-mediated diseases.
Johnson & Johnson said the deal would broaden the position of its Janssen Pharmaceutical Cos. unit in immune-mediated diseases and allow the unit to expand into autoantibody-driven disease.
Momenta's lead asset, nipocalimab, recently received rare-pediatric-disease designation from the U.S. Food and Drug Administration for the prevention of hemolytic disease of the fetus and newborn, a serious blood disorder. Johnson & Johnson said it expects nipocalimab to contribute to Janssen's goals of achieving above-market growth over the mid and long term.
Johnson & Johnson said it expects to complete the acquisition by the end of the year.
Shares of Momenta surged 68% to $51.86 in premarket trading Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 19, 2020 07:06 ET (11:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Momenta Pharmaceuticals Chart |
1 Month Momenta Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions